Aclarion Reports 196% Surge in Nociscan Scans, Advances Reimbursement and Clinical Trials
Aclarion's Q1 2026 results show a 196% year-over-year increase in Nociscan scan volumes, driven by clinical adoption and payer coverage, with a strong cash position and upcoming CLARITY trial data expected in late 2026.
Aclarion, Inc. (Nasdaq: ACON, ACONW) reported first quarter 2026 financial results on April 30, highlighting a 196% year-over-year increase in Nociscan scan volumes, signaling accelerating clinical adoption of its biomarker and AI platform for chronic low back pain. The company also announced a $2.5 million share repurchase program and a strong balance sheet with $19.0 million in cash and no debt, providing runway into the second half of 2027.
The triple-digit growth reflects both new account activation and deeper utilization at existing sites, indicating that Nociscan is becoming more integrated into clinical workflows. According to the company, approximately 5.8 million lumbar MRIs are performed annually in the U.S. for low back pain, representing a potential $2 billion market opportunity for technologies like Nociscan that offer objective, data-driven evaluation of discogenic pain.
Reimbursement progress is a key catalyst. Nociscan has been reimbursed for several months by Vitality, AXA, and Aviva—three of the four largest private insurers in the U.K. This early payer adoption provides validation and a pathway for broader coverage expansion. In the U.S., the company continues to engage with payers through the Nociscan Reimbursement Program to establish coverage pathways.
Clinically, Aclarion is advancing the CLARITY randomized trial, designed to validate Nociscan's utility in guiding treatment decisions. A preliminary internal readout is expected in the second half of 2026, with public disclosure of early interim results anticipated in late 2026. The company also has seven ongoing clinical trials and multiple investigator-initiated real-world evidence trials to support reimbursement discussions and potential local coverage decisions by commercial insurers.
On the intellectual property front, Aclarion strengthened its portfolio with a new patent covering the use of AI in future product workflows, bringing its total to 64 issued and pending patents worldwide. This is expected to enhance gross margins and scalability.
Financially, as of March 31, 2026, the company had 2,444,871 common shares outstanding (2,882,371 on a fully diluted basis), translating to approximately $6.60 per share in cash. The $2.5 million stock buyback program announced this week underscores management's confidence in the company's growth trajectory.
Brent Ness, CEO of Aclarion, commented: 'Q1 represents a clear inflection for Aclarion. Scan volume growth accelerated significantly, driven by increasing physician adoption and stronger execution with our recently hired Commercial Directors in the UK and the Eastern US. Importantly, we are still in the early stages of commercializing Nociscan into a large and underpenetrated market.'
The latest updates on Aclarion can be found in the company's newsroom at https://tinyurl.com/aconnewsroom. For more information on Nociscan, visit www.aclarion.com.